Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in Bone Marrow Failure Syndromes
NCT00001962Phase 2Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 1999
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclizumab in aplastic anemia, pure red cell aplasia (PRCA) and Diamond-Blackfan anemia (DBA), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Hematologic Response at 3 months. Started Nov 1999; status: terminated.
02
Drugs
daclizumab
03
Conditions
aplastic anemiapure red cell aplasia (PRCA)Diamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT00001962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001962.